Differences in sarcopenia prevalence between upper-body and lower-body based EWGSOP2 muscle strength criteria: the Tromsø study 2015–2016

• Main Authors: Johansson, Jonas, Strand, Bjørn Heine, Morseth, Bente, Hopstock, Laila Arnesdatter, Sameline Grimsgaard
• Format: Article in Journal/Newspaper
• Language: unknown
• Published: figshare 2020
• Subjects: Biotechnology; 59999 Environmental Sciences not elsewhere classified; FOS Earth and related environmental sciences; Ecology; FOS Biological sciences; Science Policy; 111714 Mental Health; FOS Health sciences; Tromsø
• Online Access: https://dx.doi.org/10.6084/m9.figshare.c.5203257.v1; https://springernature.figshare.com/collections/Differences_in_sarcopenia_prevalence_between_upper-body_and_lower-body_based_EWGSOP2_muscle_strength_criteria_the_Troms_study_2015_2016/5203257/1

Abstract Background The European Working Group on Sarcopenia in Older People (EWGSOP2) recommends grip strength and chair stand tests to be used as primary defining measures. It is unclear how either test affects prevalence estimates. Methods This cross-sectional study involved 3498 community-dwelling participants (40–84 years) from the 7th Tromsø Study survey (2015–2016). We used grip strength, five-repetition chair stands, four-meter Walk Speed Test, Timed-Up-and-Go (TUG) and Dual-Energy X-ray Absorptiometry measurements. Data were analyzed using multiple linear regression models and ROC-curves. Results Probable and confirmed sarcopenia prevalence was 1.3 and 4.4% based on grip strength and chair stands, respectively. There was very low agreement between grip strength and chair stand cut-offs (κ = 0.07), with only 4.3% of participants defined as having probable sarcopenia overlapping in the two criteria. Participants with grip strength-based sarcopenia had lower mean height, weight, waist circumference, and appendicular lean mass relative to body height (ALMheight2) than non-sarcopenic participants (all p